Cancer is composed of multiple cell populations with different genomes. This phenomenon called intratumor heterogeneity (ITH) is supposed to be a fundamental cause of therapeutic failure. Therefore, its principle-level understanding is a clinically important issue. To achieve this goal, an interdisciplinary approach combining genome analysis and mathematical modeling is essential. For example, we have recently performed multiregion sequencing to unveil extensive ITH in colorectal cancer.
| INTRODUCTION
Cancer is composed of multiple cell populations with different genomes. Each of the populations is called a clone (or subclone) and this phenomenon is called intratumor heterogeneity (ITH). ITH is observed in various types of cancers and is presumed to be a major cause leading to therapeutic resistance. If a tumor harbors a major clone sensitive to a specific anti-cancer treatment, the tumor shrinks within a given period after the treatment. However, in most cases, a minor clone resistant to the chemotherapy exists in the tumor and predominantly regrows despite the intensive therapy. It is supposed that ITH can be generated by clonal branching during cancer evolution.
In 1976, Nowell proposed that clones acquiring somatic mutations were subject to natural selection in a stepwise manner, by which cancer could originate from a single normal cell. 1 The samples from metastatic and recurrent lesions of the same patient are also sequenced along with a primary lesion. By multiregion sequencing, 2 categories of somatic single nucleotide mutations,
"founder" and "progressor" mutations, are identified. These are present in all or some of the regions, respectively (they are also referred to by different terms in different studies: e.g. public and private mutations, respectively). Founder mutations are assumed to accumulate in the early phase of cancer evolution. The common ancestor clone that has acquired all the founder mutations then branches into subclones, which accumulate progressor mutations and contribute to the formation of ITH. Through these multiregion mutational profiles, we can infer an evolutionary history of the cancer by constructing a phylogenetic tree. For example, whole exome multiregion sequencing using multiple samples from primary and metastatic lesions in each of 10 renal cancer patients unveiled extensive ITH and divergent clonal evolution in renal cancer. 4, 5 Their study also revealed founder non-silent mutations in some known driver genes such as VHL as well as progressor non-silent mutations in other known driver genes such as SETD and BAP1. It is intriguing that, in some cases, independent mutations on different positions of the same driver gene were acquired by parallel evolution, strongly suggesting that a part of the ITH was generated by Darwinian evolution. We can also obtain information on ITH by performing deep sequencing in a sample from 1 region of a tumor ( Figure 2 ). prostate cancers [45] [46] [47] [48] [49] [50] and urothelial carcinomas, 51 as summarized comprehensively in a previous review. 52 We also performed whole exome multiregion sequencing in 9 cases of colorectal cancers to identify founder and progressor mutations in each case. 53 The result obtained from 1 of the 9 cases is shown in Figure 3 . Progressor mutations showed a mutational pattern which was geographically correlated with sampling locations. Moreover, we found that, in each region, founder mutations existed as clonal mutations while progressor mutations existed as subclonal mutations. This finding suggests that, even in each region, there existed ITH which was not captured by the resolution of multiregion sequencing. In addition, most of the mutations of known driver genes, such as APC and KRAS, were found to be founder mutations. Progressor mutations contained few driver mutations and parallel evolution was not confirmed, which is in contrast to the findings obtained in renal cancer. Moreover, frequent parallel evolutions were demonstrated in prostate cancer and low-grade glioma but not in other kinds of cancer, suggesting that the origin of ITH cannot solely be explained by Darwinian evolution.
| EXPLORIN G EVOLUTION ARY PRINCIPLES UNDERLYING IN TR ATUMOR HETEROGEN EITY BY MATHEMATICAL MODELING
As described above, genome analysis has unveiled extensive ITH in various types of tumors. However, genome analysis is not sufficient
for understanding how ITH is generated. To answer this question, mathematical modeling is a powerful tool when combined with genomic analysis. Next, we introduce some of the mathematical modeling studies that have sought to clarify the evolutionary principles underlying ITH.
Mathematical modeling can give us insights into system-level principles underlying a phenomenon and is widely employed in the natural sciences and engineering disciplines as well as in the social sciences. In a mathematical modeling study, we start from expressing a target dynamic system as a mathematical model, using mathemati- 
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Because the existing models could not completely reproduce the extensive ITH revealed by our multiregion sequencing of colorectal cancer, we developed a new agent-based model, the branching evolutionary process (BEP) model, to simulate heterogeneous cancer evolution. 53 In a way similar to the other models, the BEP model assumes cells to be agents ( Figure 4A ). Each cell harbors n genes including d driver genes, while each cell divides and dies in a unit time with a probability p and q, respectively. When the cell divides, each gene is mutated with probability r, and if any driver genes are mutated, the division probability p increases 10 f -fold per mutation.
In the BEP model, f can be regarded as the strength of the driver genes. Given that a cell without mutations divides according to this rule, after the normal cell acquires the first driver mutation, which accelerates cell division, the proportion of the clone originating from the cell increases in a whole cell population. By repeating these steps, each cell gradually accumulates driver mutations as well as accompanying passenger mutations, which do not affect the cell division rate, and, finally, a tumor is formed with numerous mutations To explore the principles of ITH generation, we performed a large number of BEP simulations using a supercomputer with various parameter settings to find conditions leading to the extensive ITH observed in our genomic analyses. As a result, when cancer evolution was simulated with an assumption of a high mutation rate (i.e.
with a large r value), followed by computer simulation of multiregion sequencing, we could reproduce mutation profiles similar to those obtained by our multiregion sequencing of colorectal cancers (Figure 5A,B) . That is, irrespective of the presence of founder mutations, progressor mutations contributed to the formation of a heterogeneous mutation profile, which was geographically correlated with sampling locations. Moreover, we could also reconstruct local heterogeneity, as illustrated by the finding that progressor mutations existed as subclonal mutations in each region. Intriguingly, while driver mutations were acquired as founder mutations, progressor mutations contained few driver mutations and most of them consisted of neutral mutations that did not affect the cell division rate. This suggests that, after the appearance of the common ancestor clone with accumulated driver mutations, extensive ITH was generated by neutral evolution. In neutral evolution, which was introduced by Motoo Kimura, 57 neutral mutations that are neither advantageous nor disadvantageous for survival and growth prevail in a population by chance. This contrasts with classical Dawinian evolution, which is caused by natural selection; therefore, when introduced, the neutral evolution theory was strongly opposed by supporters of Darwinian evolution theory. However, it is currently well-accepted that most of 
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F I G U R E 3 Multiregion sequencing of colorectal cancer. A, A schema of a multiregion sampling in a primary colorectal cancer and matched metastatic liver lesion. In this case, we obtained 20 samples from the primary lesion and 1 sample from the metastatic lesion. B, A multiregion mutation profile. The depth of red represents mutant allele frequency while the colors of sample labels were prepared so that the similarities of colors represent those of mutation patterns. C, A phylogenetic tree constructed from the multiregion mutation profile. The time when mutations in known driver genes of colorectal cancer is acquired is indicated along the tree NIIDA ET AL.
| 887 the genetic diversity among biological species is generated by neutral evolution. Moreover, single-cell mutation profiles of the simulated tumor suggest that the tumor consists of a large number of minute clones with numerous neutral mutations accumulated ( Figure 5C ). This extensive ITH generated by neutral mutation could be a fundamental cause of therapeutic failure. Because whether a mutation is neutral or not depends on the surrounding environment, an environmental change induced by a specific therapy can convert a neutral mutation which has no effect before the therapy to a driver mutation leading to therapeutic refractoriness (resistant mutation). This means that any type of therapy can potentially generate a resistant clone with a resistant mutation, which leads to the tumor relapse even if the therapy is temporarily effective (Figure 6 ). Similar to our study, there is a recent report demonstrating the presence of uniformly high ITH in colorectal tumors unveiled by genome analysis through multiregion and deep sequencing. 26 Moreover, the authors found that progressor mutations identified in some regions were often scattered in geographically separated regions as subclonal mutations of low allele frequencies. This phenomenon could be reproduced by computer simulation, and the Big Bang model was proposed. In the Big Bang model, a large number of subclones are generated in the early phase of cancer evolution, and then these subclones expand without natural selection, while partially mixing, to eventually show uniformly high ITH in every region of the tumor. Another study involving liver cancers demonstrated that a statistic value indicative of clonal diversity in multiregion sequencing data was consistent with a theoretical value derived analytically from the neutral evolution model. 32 The claim that neutral evolution accumulated numerous mutations in the tumor is consistent with ours. An approach to test the neutrality using deep sequencing data has also been proposed. 58 Mathematical modeling to analyze multiregion sequence data, 59 where the distributions of allele frequencies in 2 separate regions of a single tumor were examined together to discriminate between Darwinian and neutral evolution. The researchers analyzed multiregion sequencing data to find evolutionary modes specific to different tumor types while simulation of cancer evolution and multiregion sequencing were employed to benchmark the proposed approach. In addition to the cancer type-specific observation of parallel evolution, these results showed that the neutral evolution model was evident in some types of tumors while the contribution of Darwinian evolution was prominent in other types. However, the reason why the evolutionary principles underlying ITH differ in different types of cancers remains unclear.
We expect that mathematical modeling will be a promising and powerful tool for gaining an insight into this issue. Given that a tumor is composed of major and minor clones which are sensitive and resistant to the chemotherapy, respectively, the tumor temporarily shrinks because the major chemosensitive clone is eradicated. However, as the major chemosensitive clone disappears, the minor resistant clone can grow freely due to the release from growth competition; that is, the competitive relationship between the 2 clones is dissolved. On the other hand, if we can Note that the simulated profile is similar to the real one obtained from the colorectal cancer ( Figure 3B ), and that driver mutations consisted only of founder mutations. C, A simulated single-cell mutation profile of the simulated tumor, suggesting the existence of numerous clones that cannot be detected by multiregion sequencing F I G U R E 6 Acquisition of therapeutic resistance by neutral evolution. Among numerous subclones generated by neutral evolution, a resistant clone emerges and expands at an accelerated pace, thereby leading to tumor relapse keep the 2 clones in a competitive state while controlling the total tumor volume within an acceptable threshold, the survival of the patient can be prolonged as compared with the routine continuous administration. Thus, the usefulness of several alternative treatment regimens has been proposed by mathematical modeling. 60, 61 For example, in "adaptive therapy", the initial dose of an anti-cancer drug is high and then the dosage is decreased as the tumor shrinks to eventually maintain the sensitive clone at a level sufficient to suppress the growth of the resistant clone. 62 Similarly, in "metronomic therapy" an anti-cancer drug is continuously administered in a low dose. 63 Treatment regimens using a combination of drugs are also proposed as exemplified by "double bind therapy." In this therapy, 2 different kinds of drugs are administered alternately to expose each of the 2 clones to their respective effective drugs, which can theoretically keep the tumor volume at a constant level. 64 When combined with novel findings obtained by recent advances in genome analysis, these treatment strategies can be further refined. In particular, liquid biopsy based on circulating tumor DNA (ctDNA) appears to be an essential tool for monitoring the efficacy of the treatment and for detecting recurrences in the early phases. 65 ctDNA is also referred to as a tumor-derived portion of cell-free DNA (cfDNA), which is all non-encapsulated DNA circulating in the bloodstream. By applying digital PCR or deep sequencing to cfDNA extracted from patients' plasma, we can non-invasively detect mutations in ctDNA. The allele frequencies of the mutations in ctDNA are supposed to reflect the real-time clonal proportions in the whole tumor, including primary and metastatic lesions, which can provide an opportunity for tracking the temporal dynamics of ITH during a therapeutic course. For example, the time-series data acquired by digital PCR of ctDNA showed the emergence of a resistant KRAS mutation during anti-EGFR therapy in colorectal cancer patients. 66 Moreover, mathematical analysis of the time-series data suggested that the KRAS mutation already existed in the tumor before the initiation of chemotherapy, which is consistent with the view derived from our neutral evolution model ( Figure 6 ).
In a recent study designed to combine multiregion sequencing of the tumor and deep sequencing of ctDNA, 37 first, surgical samples of early-stage lung cancer were analyzed by multiregion sequencing to identify target mutations which can trace existent clones in the primary tumors. Then, deep sequencing of the target mutations was performed using time-series ctDNA samples after the surgery.
The researchers succeeded in unveiling the clonal evolutionary dynamics during the treatment period to the eventual tumor relapse. These time-series analyses utilizing ctDNA-based liquid biopsy are expected to give us deeper insight into the heterogeneous cancer evolution responsible for therapeutic failure and are indispensable for the realization of anti-cancer therapies based on mathematical modeling.
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